Kimiaki Takagi

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 14

Top Topics

Combination Therapy

Metastatic Renal Cell Carcinoma

Radical Prostatectomy

Top Venues

Current oncology (Toronto, Ont.)

Diseases (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Naotaka Kumada, Koji Iinuma, Yasuaki Kubota, Kimiaki Takagi, Masahiro Nakano, Takashi Ishida, Shigeaki Yokoi, Fumiya Sugino, Makoto Kawase, Shinichi Takeuchi, Kota Kawase, Daiki Kato, Manabu Takai, Yuki Tobisawa, Takayasu Ito, Keita Nakane, Takuya Koie
Impact of Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study. Diseases (Basel, Switzerland) 12 (6) (2024)
Naotaka Kumada, Koji Iinuma, Yasuaki Kubota, Kimiaki Takagi, Masahiro Nakano, Takashi Ishida, Shigeaki Yokoi, Fumiya Sugino, Makoto Kawase, Shinichi Takeuchi, Kota Kawase, Daiki Kato, Manabu Takai, Yuki Tobisawa, Takayasu Ito, Keita Nakane, Takuya Koie
Impact of Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study. Diseases (Basel, Switzerland) 12 (6) (2024)
Naotaka Kumada, Koji Iinuma, Yasuaki Kubota, Kimiaki Takagi, Masahiro Nakano, Takashi Ishida, Shigeaki Yokoi, Fumiya Sugino, Makoto Kawase, Shinichi Takeuchi, Kota Kawase, Daiki Kato, Manabu Takai, Yuki Tobisawa, Takayasu Ito, Keita Nakane, Takuya Koie
Impact of Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study. Diseases (Basel, Switzerland) 12 (6) (2024)
Koji Iinuma, Toyohiro Yamada, Koji Kameyama, Tomoki Taniguchi, Kei Kawada, Takashi Ishida, Shingo Nagai, Torai Enomoto, Shota Ueda, Kimiaki Takagi, Makoto Kawase, Shinichi Takeuchi, Kota Kawase, Daiki Kato, Manabu Takai, Keita Nakane, Takuya Koie
The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study. Cancers 15 (3) (2023)
Koji Iinuma, Toyohiro Yamada, Koji Kameyama, Tomoki Taniguchi, Kei Kawada, Takashi Ishida, Shingo Nagai, Torai Enomoto, Shota Ueda, Kimiaki Takagi, Makoto Kawase, Shinichi Takeuchi, Kota Kawase, Daiki Kato, Manabu Takai, Keita Nakane, Takuya Koie
The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study. Cancers 15 (3) (2023)
Makoto Kawase, Kimiaki Takagi, Kei Kawada, Takashi Ishida, Masayuki Tomioka, Torai Enomoto, Shota Fujimoto, Tomoki Taniguchi, Hiroki Ito, Koji Kameyama, Toru Yamada, Kota Kawase, Daiki Kato, Manabu Takai, Koji Iinuma, Keita Nakane, Takuya Koie
Clinical Lymph Node Involvement as a Predictor for Cancer-Specific Survival in Patients with Penile Squamous Cell Cancer. Current oncology (Toronto, Ont.) 29 (8) (2022)
Risa Tomioka-Inagawa, Keita Nakane, Torai Enomoto, Masayuki Tomioka, Tomoki Taniguchi, Takashi Ishida, Kaori Ozawa, Kimiaki Takagi, Hiroki Ito, Shinichi Takeuchi, Makoto Kawase, Kota Kawase, Daiki Kato, Manabu Takai, Koji Iinuma, Shigeaki Yokoi, Masahiro Nakano, Takuya Koie
The Impact of Neutrophil-to-Lymphocyte Ratio after Two Courses of Pembrolizumab for Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma. Biomedicines 10 (7) (2022)
Toyohiro Yamada, Keita Nakane, Torai Enomoto, Masayuki Tomioka, Tomoki Taniguchi, Takashi Ishida, Kaori Ozawa, Kimiaki Takagi, Hiroki Ito, Shinichi Takeuchi, Makoto Kawase, Kota Kawase, Daiki Kato, Manabu Takai, Koji Iinuma, Shigeaki Yokoi, Masahiro Nakano, Takuya Koie
Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study. Biomedicines 10 (9) (2022)
Koji Iinuma, Koji Kameyama, Tomoki Taniguchi, Kei Kawada, Takashi Ishida, Kimiaki Takagi, Shingo Nagai, Torai Enomoto, Masayuki Tomioka, Makoto Kawase, Shinichi Takeuchi, Daiki Kato, Manabu Takai, Keita Nakane, Takuya Koie
Effectiveness and Safety of Molecular-Targeted Therapy after Nivolumab Plus Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study. Cancers 14 (19) (2022)
Kimiaki Takagi, Makoto Kawase, Daiki Kato, Kota Kawase, Manabu Takai, Koji Iinuma, Keita Nakane, Noriyasu Hagiwara, Toru Yamada, Masayuki Tomioka, Takuya Koie
Robot-Assisted Radical Prostatectomy for Potential Cancer Control in Patients with Metastatic Prostate Cancer. Current oncology (Toronto, Ont.) 29 (4) (2022)
Kimiaki Takagi, Azumi Naruse, Kazutoshi Akita, Yuka Muramatsu-Maekawa, Kota Kawase, Takuya Koie, Masanobu Horie, Arizumi Kikuchi
CALN1 hypomethylation as a biomarker for high-risk bladder cancer. BMC urology 22 (1) (2022)
Koji Iinuma, Koji Kameyama, Kei Kawada, Shota Fujimoto, Kimiaki Takagi, Shingo Nagai, Hiroki Ito, Takashi Ishida, Makoto Kawase, Kota Kawase, Chie Nakai, Daiki Kato, Manabu Takai, Keita Nakane, Takuya Koie
Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study. Current oncology (Toronto, Ont.) 28 (2) (2021)
Koji Iinuma, Torai Enomoto, Kei Kawada, Shota Fujimoto, Takashi Ishida, Kimiaki Takagi, Shingo Nagai, Hiroki Ito, Makoto Kawase, Chie Nakai, Kota Kawase, Daiki Kato, Manabu Takai, Keita Nakane, Koji Kameyama, Takuya Koie
Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab. Journal of clinical medicine 10 (22) (2021)
Kimiaki Takagi, Masashi Mizuno, Kota Kawase, Kenichi Minoshima, Masayoshi Yamaha, Masanobu Horie
Impact on survival of urgent dialysis initiation in patients with end-stage renal disease: a case-control study. Clinical and experimental nephrology 24 (12) (2020)